Skip to main content

Adverse Events

Online Only
Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma
Original Research, Adverse Events, Disparities in Oncology, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma
April 2026 Vol 19, No 2
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and Europe.
Laura Fan Sun, PharmD, BCOP; Natalie Brumwell, PharmD; Kevin Hall, PharmD; Kristina Murphy, PharmD; Jeffrey Switchenko, PhD; Yichun Cao, MPH; Vikas Gupta, MD, PhD; Madhav Dhodapkar, MBBS; Nisha Joseph, MD; Craig Hofmeister, MD, MPH; Jonathan Kaufman, MD; Ajay Nooka, MD, MPH, FACP; Sagar Lonial, MD; Kathryn Maples, PharmD
Read More ›
Educating NSCLC Patients on Adverse Event Management
Best Practices in Lung Cancer Navigation
Educating NSCLC Patients on Adverse Event Management
By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP
Interview with the Innovators, Lung Cancer, Adverse Events
Videos
Educating patients about cancer- and treatment-related side effect management
Read More ›